Mirum Pharmaceuticals
MIRM
146 hedge funds and large institutions have $956M invested in Mirum Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 58 increasing their positions, 28 reducing their positions, and 9 closing their positions.
322% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 9
107% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 28
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
25% more funds holding
Funds holding: 117 → 146 (+29)
15% more capital invested
Capital invested by funds: $833M → $956M (+$123M)
5.77% more ownership
Funds ownership: 91.37% → 97.14% (+5.8%)
64% less call options, than puts
Call options by funds: $486K | Put options by funds: $1.33M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$37.2M |
| 2 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$24.3M |
| 3 |
CCM
Cadian Capital Management
New York
|
+$14.1M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$13.3M |
| 5 |
William Blair Investment Management
Chicago,
Illinois
|
+$8.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$53.2M |
| 2 |
DM
Deerfield Management
New York
|
-$48.8M |
| 3 |
Axa
Paris,
France
|
-$5.84M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$5.21M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.72M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Balyasny Asset Management
Chicago,
Illinois
| – | -$246K | -10,250 | Closed |
|
|
VFA
152
Values First Advisors
Gray,
Tennessee
| – | -$204K | -8,497 | Closed |
|
|
BAM
153
Belpointe Asset Management
Reno,
Nevada
| – | -$67.3K | -2,800 | Closed |
|
|
C
154
Covestor
London,
United Kingdom
| – | +$106 | +4 | New |
|
MIRM Hedge Fund Activity: Q2 2023 in Review
146 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q2 2023, worth a combined $956M — up 15% from $833M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new MIRM positions and 9 closed out — a net gain of 29 holders — while 58 added to existing stakes and 28 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $37.2M. The largest seller was NEA Management Company, cutting an estimated $53.2M.
- 146 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q2 2023, up from 117 in Q1 2023.
- Funds reported $956M of Mirum Pharmaceuticals stock for Q2 2023, up 15% quarter-over-quarter.
- 38 funds opened new Mirum Pharmaceuticals positions in Q2 2023 and 9 closed out, a net change of +29 holders.
- The largest Mirum Pharmaceuticals buyer in Q2 2023 was Eventide Asset Management, an estimated $37.2M added.
- The largest Mirum Pharmaceuticals seller in Q2 2023 was NEA Management Company, an estimated $53.2M sold.
Based on aggregated 13F filings for Q2 2023.